Literature DB >> 7316272

Responses of elderly subjects to monovalent A/USSR/77 (H1N1) and Trivalent A/USSR/77 (H1N1)-A/TEXAS/77 (H3N2)-B/Hong Kong/72 vaccines.

M W Brandriss, R F Betts, U Mathur, R G Douglas.   

Abstract

Antibody responses to vaccination with monovalent A/USSR/77 (H1N1) and trivalent A/USSR/77 (H1N1)-A/Texas/77 (H3N2)-B/Hong Kong/72 vaccines were examined in a group of elderly persons most of whom had received more than 1 influenza vaccination in the previous 5 yr. Seventy-two per cent had a fourfold or greater increase in hemagglutination inhibition (HA1) titer to A/USSR and 92% had postvaccine titers equal to or greater than 1:40. There were no differences in antibody responses to A/USSR between recipients of monovalent and trivalent vaccines. No booster effect of a second injection of A/USSR was observed in subjects who had failed to respond to the first injection. Although there was a significant correlation between postvaccine HAI titers to A/USSR and to A/Texas, the responses to A/Texas and B/Hong Kong were modest or minimal compared with those to A/USSR. This serologic data may be relevant to the results of surveillance studies that suggest a limited advantage of repeated vaccinations with H3N2 subtypes and should help in evaluating the results of this practice.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7316272     DOI: 10.1164/arrd.1981.124.6.681

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  10 in total

1.  Characterization of humoral and cellular immune features of gamma-irradiated influenza vaccine.

Authors:  Fengjia Chen; Ho Seong Seo; Hyun Jung Ji; Eunji Yang; Jung Ah Choi; Jae Seung Yang; Manki Song; Seung Hyun Han; Sangyong Lim; Jae Hyang Lim; Ki Bum Ahn
Journal:  Hum Vaccin Immunother       Date:  2020-07-09       Impact factor: 3.452

2.  Systemic and local antibody responses in elderly subjects given live or inactivated influenza A virus vaccines.

Authors:  D C Powers; S D Sears; B R Murphy; B Thumar; M L Clements
Journal:  J Clin Microbiol       Date:  1989-12       Impact factor: 5.948

3.  Safety of and serum antibody response to cold-recombinant influenza A and inactivated trivalent influenza virus vaccines in older adults with chronic diseases.

Authors:  G J Gorse; R B Belshe; N J Munn
Journal:  J Clin Microbiol       Date:  1986-09       Impact factor: 5.948

4.  Immunization of elderly people with two doses of influenza vaccine.

Authors:  P A Gross; M E Weksler; G V Quinnan; R G Douglas; P F Gaerlan; C R Denning
Journal:  J Clin Microbiol       Date:  1987-09       Impact factor: 5.948

5.  Time to peak serum antibody response to influenza vaccine.

Authors:  S Rastogi; P A Gross; J Bonelli; S Dran; R A Levandowski; C Russo; M E Weksler; D Kaye; M Levison; E Abrutyn
Journal:  Clin Diagn Lab Immunol       Date:  1995-01

6.  Local and systemic antibody responses in high-risk adults given live-attenuated and inactivated influenza A virus vaccines.

Authors:  G J Gorse; R B Belshe; N J Munn
Journal:  J Clin Microbiol       Date:  1988-05       Impact factor: 5.948

7.  Increased immunogenicity of inactivated influenza virus vaccine containing purified surface antigen compared with whole virus in elderly women.

Authors:  D C Powers
Journal:  Clin Diagn Lab Immunol       Date:  1994-01

Review 8.  Vaccine-induced antibody responses as parameters of the influence of endogenous and environmental factors.

Authors:  H Van Loveren; J G Van Amsterdam; R J Vandebriel; T G Kimman; H C Rümke; P S Steerenberg; J G Vos
Journal:  Environ Health Perspect       Date:  2001-08       Impact factor: 9.031

9.  A comparative analysis of influenza vaccination programs.

Authors:  Shweta Bansal; Babak Pourbohloul; Lauren Ancel Meyers
Journal:  PLoS Med       Date:  2006-10       Impact factor: 11.069

10.  Antibody response to influenza A(H1N1)pdm09 among healthcare personnel receiving trivalent inactivated vaccine: effect of prior monovalent inactivated vaccine.

Authors:  Manjusha Gaglani; Sarah Spencer; Sarah Ball; Juhee Song; Allison Naleway; Emily Henkle; Sam Bozeman; Sue Reynolds; Wendy Sessions; Kathy Hancock; Mark Thompson
Journal:  J Infect Dis       Date:  2013-12-19       Impact factor: 5.226

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.